Combining minimally invasive interval debulking surgery with the life-extending benefits of hyperthermic intraperitoneal chemotherapy for appropriate candidates with epithelial ovarian cancer that has spread to the abdominal cavity. In this article, Chad Michener, MD, explains the minimally invasive technique.
HIPEC improves survival, though careful intraoperative management is key. Robert DeBernardo, MD, explains the results of a HIPEC study presented at the Society for Gynecologic Oncology’s Annual Meeting.
The Cleveland Clinic Center for Research Excellence in Gynecologic Cancer (CREGC) is a collaborative network for the development of a comprehensive research program to promote the translation of basic science investigation into the clinic.
Hyperthermic intraperitoneal chemotherapy for advanced ovarian cancer has been shown to improve survival. Learn more about HIPEC from the experts at this hands-on program with anatomy lab June 21-22 at Cleveland Clinic.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
HIPEC has already been shown effective in recurrent ovarian cancer. A new trial shows for the first time that HIPEC improved outcomes for women with newly diagnosed advanced cancer too.
Heated chemotherapy (HIPEC) plus cytoreductive surgery can extend survival and reduce morbidity in patients with many forms of advanced abdominal cancer.
Cleveland Clinic Florida has established a hyperthermic intraperitoneal chemotherapy (HIPEC) program to expand access to this potentially lifesaving procedure. Discover if HIPEC is right for your patients.
Hyperthermic intraperitoneal chemotherapy, which involves the intraoperative delivery and circulation of heated cancer drugs, is showing promise for cancers of the peritoneal cavity arising from gynecologic cancers. The technique is a welcome development in the treatment of a disease whose outcome has changed little in the past two decades.